The HNSCC patient population with high EPHB4-low EFNB2 showed a significant increase in the overall survival compared to the low EPHB4-high EFNB2 cohort (Hazard ratio: 0.4328; CI: 0.2921–0.6411; p-value: <0.0001) (Fig. 9c). Here, EFNB2 is linked to head and neck squamous cell carcinoma.